Omega Fund Management 13F annual report

Omega Fund Management is an investment fund managing more than $178 billion ran by Alexia Pearsall. There are currently 12 companies in Mrs. Pearsall’s portfolio. The largest investments include Replimune Inc and Nuvation Bio, together worth $96.8 billion.

$178 billion Assets Under Management (AUM)

As of 7th August 2023, Omega Fund Management’s top holding is 3,001,319 shares of Replimune Inc currently worth over $69.7 billion and making up 39.0% of the portfolio value. Relative to the number of outstanding shares of Replimune Inc, Omega Fund Management owns less than approximately 0.1% of the company. In addition, the fund holds 15,072,340 shares of Nuvation Bio worth $27.1 billion. The third-largest holding is Alpine Immune Sciences Inc worth $20.9 billion and the next is Morphic Inc worth $17.8 billion, with 309,846 shares owned.

Currently, Omega Fund Management's portfolio is worth at least $178 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Omega Fund Management

The Omega Fund Management office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Alexia Pearsall serves as the Chief Financial Officer, Omega Fund Management, LLC at Omega Fund Management.

Recent trades

There are companies that Omega Fund Management is getting rid of from its portfolio. Omega Fund Management closed its position in Imago Biosciences on 14th August 2023. It sold the previously owned 3,018,737 shares for $45.4 million. Alexia Pearsall also disclosed a decreased stake in Replimune Inc by 0.3%. This leaves the value of the investment at $69.7 billion and 3,001,319 shares.

One of the smaller hedge funds

The two most similar investment funds to Omega Fund Management are American Trust Investment Advisors and Addison Advisors. They manage $179 billion and $178 billion respectively.

Alexia Pearsall investment strategy

Omega Fund Management’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 69.9% of the total portfolio value. The fund focuses on investments in the United States as 58.3% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are small-cap stocks. Stocks with a size of more than $100 million in market cap make up 25% of the total holdings value. On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $398 million.

The complete list of Omega Fund Management trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Replimune Group Inc	30.01% 3,001,319	$69,690,627,000	39.05%
Nuvation Bio	No change 15,072,340	$27,130,212,000	15.20%
Alpine Immune Sciences Inc	No change 2,029,580	$20,864,082,000	11.69%
Morphic Holding Inc	48.16% 309,846	$17,763,471,000	9.95%
Ikena Oncology	No change 2,249,123	$14,754,247,000	8.27%
Theseus Pharmaceuticals	No change 711,479	$6,638,099,000	3.72%
Kronos Bio, Inc.	No change 3,818,283	$6,567,447,000	3.68%
Sana Biotechnology, Inc.	No change 843,750	$5,028,750,000	2.82%
Spruce Biosciences, Inc.	No change 2,161,022	$4,646,197,000	2.60%
Immunic, Inc.	No change 1,788,160	$4,488,282,000	2.51%
Syros Pharmaceuticals Inc.	No change 251,270	$791,500,000	0.44%
Senti Biosciences, Inc.	No change 195,792	$122,762,000	0.07%
Imago Biosciences	Closed 3,018,737	$45,432,000
Cincor Pharma	Closed 560,985	$18,412,000
Gossamer Bio, Inc.	Closed 1,500,000	$17,970,000
Paratek Pharmaceuticals Inc.	Closed 1,971,241	$5,066,000
Omega Alpha Spac	Closed 501,000	$4,975,000
Jounce Therapeutics Inc	Closed 275,513	$645,000
Essa Pharma Inc	Closed 328,196	$597,000
No transactions found
Showing first 500 out of 19 holdings